Robert Yuen Lee Ang
Strategic AdvisorDr. Robert Yuen Lee Ang, MBBS, MBA, M.D., serves as Independent Non-Executive Director at Enara Bio Limited since September 2021 and serves as its Chairman since August 2024. Dr. Ang is Independent Outside Director of Kolon TissueGene, Inc. from 2026. He was the President, Chief Executive Officer and Director of Vor Biopharma Inc. since August 2019 until June 25, 2025 and is its Strategic Advisor until October 2025 and served as its Interim Principal Financial Officer since June 21, 2024 until September 30, 2024. He is Vice Chairman of the Board of Alliance for Regenerative Medicine. He joined Vor Biopharma in 2019 from Neon Therapeutics Inc., where he served as Chief Business Officer since October 2015 until August 2019. He serves as a Board Observer of Collegium Pharmaceutical, Inc. Dr. Ang served as a Senior Associate at Frazier Healthcare Ventures. Dr. Ang worked in venture capital at Frazier Healthcare Ventures from 2008 to 2009 and Carrot Capital Healthcare Ventures from 2004 to 2006. At the firm, Dr. Ang focused on the review of biopharma investments and was a Member of the biopharma investment team. He has combined experience in operations, investments and commercialization within the healthcare industry. Prior to Neon, he served as the Senior Vice President of Business Development at Bavarian Nordic A/S from 2013 to 2015. From 2009 to 2013, Dr. Ang held various roles at Cadence Pharmaceuticals, Inc. including Vice President of Medical Affairs and Head of Business Development. He also has experience in management consulting with the Boston Consulting Group and general surgical residency training from 2000 to 2003. Dr. Ang founded Cure Therapeutics and served as its Chief Operating Officer. He led efforts in the development of a transdermal tendonitis drug through to Phase 2B product development and was primarily responsible for CMC, regulatory and intellectual property matters. Previously, he served as a Senior Associate of Carrot Capital. He served as Executive Officer at The Boston Consulting Group, Inc. In 2000, he began a surgical residency. At BCG, Dr. Ang focused on high level life science strategic projects working in the Australian medical devices, medical services, biotechnology and pharmaceutical industries along with non-healthcare industries including those in the financial services, airline and industrial goods sectors. He is a Director of the Alliance for Regenerative Medicine (“ARM”) since January 2022. Dr. Ang was involved in scientific research associated with anti-cancer vaccines. He completed his medical internship in 1999 and has surgical experience at Sir Charles Gairdner Hospital. Dr. Ang received an M.B.B.S. (Doctor of Medicine) from the University of Western Australia and an M.B.A. with Honors from Columbia Business School.
公司职务
- 公司名称Vor Biopharma Inc.股票代码VOR职务Strategic Advisor共事同僚
- JKJean-Paul KressChairman, President & CEO
- SMSandesh MahatmeChief Business Officer & CFO
- SMSiddhartha MukherjeeScientific Founder & Chairman of Scientific Advisory Board
- AOAdi OsovskyGeneral Counsel
- DBDaniella BeckmanLead Independent Director
- FNFouad NamouniIndependent Director
- AGAlexander G. CumboIndependent Director
